Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790306 | 0.87 | TSHR (0.49) | ALDH1A1CYP3A4TSHRCA1CA2 | |
| SCHEMBL27639571 | 0.86 | ALDH1A1 (0.54) | ALDH1A1CYP3A4TSHRCA1CA2 | |
| SCHEMBL2894347 | 0.85 | DTYMK (0.50) | ALDH1A1CYP3A4TSHRCA1CA2 | |
| SCHEMBL613001 | 0.85 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRCA1CA2 | |
| SCHEMBL9489644 | 0.85 | CA1 (0.50) | ALDH1A1TSHRCA1CA2TP53 | |
| SCHEMBL9489661 | 0.85 | CA1 (0.50) | ALDH1A1TSHRCA1CA2TP53 | |
| Hydrochloric Acid SCHEMBL11773238 | 0.84 | ALDH1A1 (0.51) | ALDH1A1CYP3A4TSHRCA1CA2 | |
| SCHEMBL611920 | 0.84 | ALDH1A1 (0.51) | ALDH1A1CYP3A4TSHRCA1CA2 | |
| SCHEMBL629699 | 0.83 | CA1 (0.49) | ALDH1A1CYP3A4TSHRCA1CA2 | |
| SCHEMBL8744103 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP3A4TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2607357-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120115845-A1 | THERAPEUTIC AGENTS | ALLEN JACK MCQUEEN (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| CN-101883762-A | Benzothiazoles as modulators of growth hormone releasing hormone receptors | ASTRAZENECA AB | 2010-11-10 | — | — | CN | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| EP-1406609-B1 | SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050059665-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6825185-B2 | IMPROVING THE CARDIOVASCULAR PROFILE OF A COX-2 SELECTIVE INHIBITOR BY ADMINISTERING WITH 3-HYDROXY-3- METHYLGLUTARYL COENZYME A, AN ANTIPLATELET AGENT, A THROMBIN INHIBITOR OR A THROMBOXANE INHIBITOR | NITROMED, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040116431-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-06-17 | — | — | US | disclosed |
| EP-1406609-A2 | SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406609-A4 | SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6706724-B2 | ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETIC AGENT | NITROMED, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | NICOX S.A. (FR) | 2002-08-29 | — | — | US | disclosed |
| WO-2002060378-A2 | SUBSTITUTED ARYL COMPOUNDS AS CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059665-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGES, PTGER4, PTGS1 | ALDH1A1 344/4885CYP3A4 24/4885TSHR 1154/4885 |
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | ALDH1A1 2084/4885CYP3A4 3775/4885TSHR 35/4885 |
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | PTGS2, PTGES2, PTGES | ALDH1A1 643/4885CYP3A4 48/4885TSHR 1160/4885 |
| US-20120115845-A1 | THERAPEUTIC AGENTS | GPR119, MC2R, MC4R | ALDH1A1 650/4885CYP3A4 3683/4885TSHR 230/4885 |
| US-20090186870-A1 | Therapeutic Agents - 802 | GPR119, SLC5A2, MC2R | ALDH1A1 918/4885CYP3A4 4435/4885TSHR 333/4885 |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | ALDH1A1 2084/4885CYP3A4 3775/4885TSHR 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.